Clinical Trials Browser

Recruiting × INDUSTRY × Squamous Cell Carcinoma of Head and Neck × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Recurrence

NCT04895709 2026-06-04

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05768139 2026-06-04

PIKALO-1

Phase 1/2 Recruiting

880 enrolled

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06496178 2026-06-03

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

Phase 3 Recruiting

600 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06525220 2026-06-02

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Phase 3 Recruiting

700 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT06788990 2026-06-02

FORTIFI-HN01

Phase 2/3 Recruiting

650 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT07617805 2026-06-01

DUAL-HN

Phase 1/2 Recruiting

42 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

Clinical Trials

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

PIKALO-1

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

FORTIFI-HN01

DUAL-HN

STELLAR-002

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

JADE

eVOLVE-02

AHEAD-MERIT

NEXUS-01

INVOKE

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

OP-NEU-101

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

OrigAMI-4

LUMIRAY

OrigAMI-5

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

ELUCIDATE

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

FIERCE-HN

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

STEALTH-001

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)